Sale!

Myeloproliferative Leukemia Mutation Screening MPL S505N W515L

Original price was: $226.Current price is: $168.

-26%

The Myeloproliferative Leukemia Mutation Screening for MPL S505N and W515L is a specialized genetic test that detects specific mutations in the MPL gene associated with myeloproliferative neoplasms. This comprehensive screening helps diagnose conditions like essential thrombocythemia and primary myelofibrosis by identifying critical mutations that affect platelet production and bone marrow function. The test provides essential information for accurate diagnosis, prognosis assessment, and treatment planning. Using advanced Sanger Sequencing technology, it delivers reliable results within 5-7 days from bone marrow or peripheral blood samples. At only $168 USD, this test offers valuable insights for patients experiencing unexplained blood cell abnormalities, helping guide personalized treatment approaches and improve clinical outcomes.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Myeloproliferative Leukemia Mutation Screening MPL S505N W515L

Comprehensive Genetic Testing for Myeloproliferative Disorders

The Myeloproliferative Leukemia Mutation Screening for MPL S505N and W515L represents a cutting-edge diagnostic approach for identifying specific genetic mutations associated with myeloproliferative neoplasms (MPNs). This specialized test plays a crucial role in the accurate diagnosis and management of blood disorders characterized by abnormal production of blood cells in the bone marrow.

What This Advanced Screening Detects

This comprehensive genetic analysis specifically targets two critical mutations in the MPL gene:

  • MPL S505N Mutation: A specific point mutation that affects the thrombopoietin receptor, leading to uncontrolled platelet production
  • MPL W515L Mutation: A well-characterized mutation associated with essential thrombocythemia and primary myelofibrosis

These mutations result in constitutive activation of the JAK-STAT signaling pathway, driving abnormal blood cell proliferation and contributing to the development of myeloproliferative disorders.

Who Should Consider This Genetic Screening?

Clinical Indications and Symptoms

This test is particularly recommended for individuals experiencing:

  • Unexplained elevated platelet counts (thrombocytosis)
  • Abnormal blood cell counts without clear cause
  • Family history of myeloproliferative disorders
  • Symptoms of bone marrow fibrosis or splenomegaly
  • Progressive anemia with elevated white blood cell counts
  • Constitutional symptoms including fatigue, night sweats, and weight loss
  • Previous diagnosis of essential thrombocythemia or primary myelofibrosis requiring mutation confirmation

Significant Benefits of MPL Mutation Screening

Clinical Advantages for Patients

  • Accurate Diagnosis: Provides definitive identification of MPL mutations, enabling precise classification of myeloproliferative disorders
  • Treatment Guidance: Helps determine appropriate therapeutic approaches, including JAK inhibitor eligibility
  • Prognostic Information: Offers insights into disease progression and potential complications
  • Family Risk Assessment: Assists in evaluating genetic predisposition for family members
  • Monitoring Tool: Serves as a baseline for tracking treatment response and disease evolution

Understanding Your Test Results

Interpreting Genetic Findings

Your test results will provide clear information about the presence or absence of MPL S505N and W515L mutations:

  • Positive for Mutation: Indicates the presence of one or both MPL mutations, confirming diagnosis of MPL-mutated myeloproliferative neoplasm
  • Negative for Mutation: Suggests that MPL mutations are not detected, though other genetic abnormalities may be present
  • Variant of Uncertain Significance: Rare cases where genetic changes require additional clinical correlation

All results should be discussed with your hematologist or healthcare provider for comprehensive interpretation and treatment planning.

Test Information and Pricing

Test Parameter Details
Test Name Myeloproliferative Leukemia Mutation Screening MPL S505N W515L
Regular Price $226 USD
Discount Price $168 USD
Turnaround Time 5-7 Days
Sample Type Bone Marrow/Peripheral Blood
Test Components EDTA Vacutainer (2ml)
Testing Method Sanger Sequencing

Nationwide Testing Availability

GGC DNA provides comprehensive genetic testing services across the United States, with convenient locations in all major cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art laboratories ensure consistent, high-quality results regardless of your location.

Take Control of Your Health Today

Don’t let uncertainty about blood disorders affect your quality of life. The Myeloproliferative Leukemia Mutation Screening provides critical genetic information that can guide your healthcare journey. Our experienced team is ready to assist you with convenient testing and comprehensive support.

Book your test now or call our dedicated healthcare line at +1(267) 388-9828 to schedule your appointment. Take the first step toward accurate diagnosis and personalized treatment planning.

Note: This test requires a doctor’s prescription for most cases. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel.